Exenatide sustained-release - Peptron/Yuhan Corporation

Drug Profile

Exenatide sustained-release - Peptron/Yuhan Corporation

Alternative Names: P302; PT-302; PT-304; PT-320; PT-340; SR exenatide - Peptron; YH-14617

Latest Information Update: 12 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Peptron
  • Developer Peptron; Yuhan
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Type 2 diabetes mellitus
  • Phase I Parkinson's disease
  • Preclinical Alzheimer's disease

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 10 Feb 2016 Phase-I clinical trials in Parkinson's disease in South Korea (SC, biweekly)
  • 10 Feb 2016 Preclinical trials in Type-2 diabetes mellitus in South Korea (SC, once-monthly)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top